ELIZABETH CZEREPAK - Corporate Board Profile

DELCATH SYSTEMS, INC.

Filing Date	Source Excerpt
2020-11-02	Elizabeth Czerepak was appointed as a director of the Company in February 2020. Ms. Czerepak serves as Chief Financial Officer at BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies. The current members of the Audit Committee are Elizabeth Czerepak (Chair), Steven Salamon and Roger G. Stoll.
2021-04-07	The current members of the Audit Committee are Ms. Czerepak (Chair), Mr. Salamon and Dr. Stoll. The Board has determined that each of Ms. Czerepak, Mr. Salamon and Dr. Stoll qualifies as an "audit committee financial expert" as defined by SEC rules. During 2020, the Audit Committee met four times. Each member of the Audit Committee is "independent" within the meaning of the NASDAQ listing rules and otherwise meets the financial statement proficiency requirements of the NASDAQ listing rules. The Audit Committee has a written charter, which is available on our website; go to www.delcath.com, click on "Investors," then "Corporate Governance." The current members of the Compensation and Stock Option Committee are Dr. Stoll (Chair), Ms. Czerepak and Dr. Aharon, each of whom is "independent" within the meaning of the NASDAQ listing rules. During the fiscal year 2020, our Compensation Committee engaged Pearl Meyer in an effort to better align our compensation program with best practices. The following table sets forth the compensation awarded to, earned by or paid to each non-employee director who served on our Board of Directors in 2020. Elizabeth Czerepak Fees Earned or Paid in Cash: $54,180 Option Awards: $226,500 Total: $280,680.
2022-04-04	Elizabeth Czerepak was appointed as a director of the Company in February 2020. Ms. Czerepak serves as Chief Financial Officer at BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies, since September 2020.
2023-05-01	Elizabeth Czerepak was appointed as a director of the Company in February 2020. Ms. Czerepak serves as Chief Financial Officer at BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies, since September 2020. The current members of the Audit Committee are Ms. Czerepak (Chair), Mr. Salamon and Dr. Stoll. The following table sets forth the compensation awarded to, earned by or paid to each non-employee director who served on our Board in 2022. Elizabeth Czerepak Fees Earned or Paid in Cash ($) 68,000 Option Awards($) 54,121 Total ($) 122,121.
2024-04-12	Elizabeth Czerepak was appointed as a director of the Company in February 2020. Ms. Czerepak has more than thirty-five years of financial leadership and strategy development experience across the pharmaceutical and biotechnology fields. ... The current members of the Audit Committee are Ms. Czerepak (Chair), Mr. Salamon and Dr. Stoll. ... The following table sets forth the compensation awarded to, earned by or paid to each non-employee director who served on our Board in 2023. ... Elizabeth Czerepak 63,550 124,956 188,506
2025-04-01	Elizabeth Czerepak was appointed as a director of the Company in February 2020. Ms. Czerepak has more than thirty-five years of financial leadership and strategy development experience across the pharmaceutical and biotechnology fields. The current members of the Audit Committee are Ms. Czerepak (Chair), Mr. Salamon and Dr. Martell. The Board has determined that each of Ms. Czerepak, Mr. Salamon and Dr. Martell qualifies as an “audit committee financial expert” as defined by SEC rules.